Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|September 3, 2026
ACT Brief: Human Readiness as Operational Foundation, Early Phase Capacity Consolidation, and AI-Driven Patient Matching Scale
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why many trial failures trace to human readiness gaps rather than process design alone, how CRO consolidation expands early-phase capacity, and how AI-enabled patient matching is reshaping recruitment economics.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the
pilot episode of The Human Side of Clinical Trials , Brian McGowan, PhD, chief learning officer and co-founder of ArcheMedX, introduced a framework showing why operational failures in trials often trace to gaps in human readiness rather than process design. When enrollment falls behind, protocol deviations increase, or sites struggle after activation, organizations must ask whether people were adequately prepared and equipped with genuine understanding, not just information. Fortrea announced the acquisition of Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in all-cash, adding a 200-bed clinical pharmacology unit, a bioanalytical laboratory, and biospecimen storage in Texas. The combination reduces handoffs between clinical and bioanalytical functions, improves turnaround times, and enables sponsors to run larger studies with greater operational flexibility.- In a
new contributed article , Partha Anbil and Anamika Krishanpal examined how 80% to 85% of trials miss enrollment timelines with trial delays costing $600,000 to $800,000 per day in lost revenue. AI-enabled patient matching and EHR integration are becoming operational levers, but bias, explainability, and governance will determine whether the technology scales across diverse patient populations.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Beyond Outreach: Structural Drivers of Representation in Clinical Trials
2
Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight
3
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
4
The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms
5